Appendix 4D Half Yearly Report
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Appendix 4C & Activity Report
Melbourne, Australia, 31 January 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Notification of cessation of securities
Melbourne, Australia, 21 December 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Appendix 3Y - Change of Director’s Interest Notice
Melbourne, Australia, 07 November 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
Results of Annual General Meeting 2022
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read More
CLINUVEL confirms AGM date
CLINUVEL confirms the date for the Company’s 2022 Annual General Meeting.
Read More
CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2022
CLINUVEL PHARMACEUTICALS LTD hosted an investor webinar on the financial results for...
Read More
Revenue Growth Drives CLINUVEL's Sixth Consecutive Annual Profit
CLINUVEL today announced its sixth consecutive annual net profit, driven by revenues...
Read More
Dividend/Distribution – CUV
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report
Read More
Appendix 4E & Annual Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 23 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More